Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

OPTHALMIC PHARMACEUTICAL DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories: Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 95 companies including many key and niche players such as Akorn, Inc., Alcon, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1490
Price : $4500
Companies : 95
Pages : 565
Date : October 2010
Market Data Tables : 98

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  OPTHALMIC PHARMACEUTICAL DRUGS (Complete Report) Pages : 565   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......13 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2
Data Interpretation & Reporting Level.......2
  
   Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
  
  2. INDUSTRY OVERVIEW........415 $950  
   Present Scenario and Outlook........4
Current & Future Analysis........4
Patent Expiries to Check Market Growth........4
1$100
   New Drugs to Sustain Growth........5
A Curtain Raiser........5
Drugs Developed in the Recent Past........5
1$100
   What the Future Holds in Store?........6
Where Does the Opportunity Lie?........6
In the Shifting Demographics ........6
1$100
   Which Disease Segment Offers Abundant Opportunities for R&D Initiatives........71$100
   Leading Companies & Their Areas of Research Interest/Focus........8
Business Opportunities in Ophthalmology: A Fact Sheet........8
1$100
   Impediments in Picking the Ripe & Low Hanging Opportunities........9
Low Patient Compliance........9
What’s the Antidote to Low Patient Compliance?........9
1$100
   Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?........10
An Unequivocal Discussion About Ocular Drug Design and Delivery........10
Why Understanding of the Metabolic Activity of the Eye is Important?........10
1$100
   Pitfalls of Traditional Ocular Treatment........111$100
   Ophthalmic Drug Delivery: A Recapitulation of Facts........121$100
   Antidotes to Low Delivery of Ocular Drugs & High Side Effects........13
Prodrug........13
1$100
   Soft Drugs (SDs)........14
Soft Corticosteroids........14
Drug Penetration Enhancers........14
1$100
   Chitosan Based Drugs & Drug Delivery Systems........15
How Chitosan is used to Improve Ocular Drug Retention On the Eye’s Surface?........15
1$100
   The Future of Ophthalmic Drug Delivery........16
A Straight Talk About Ophthalmic Drug Delivery Technologies........16
High Flying Expectations of Blistering Pace of Drug Development Grounded........16
1$100
   First Generation Advancements Made in Ocular Drugs........17
Second Generation Advancements Made in Ocular Drugs........17
1$100
   Limiting Factors........18
1$100
  3. MARKET DYNAMICS........197 $595  
   Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty........19
Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops........19
1$100
   Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs........201$100
   Lack of Awareness Creates Huge Burden........21
Financial Costs of Glaucoma Plague Developed and Developing Countries........21
1$100
   Aging Population & Environmental Factors Drive Growth........22
Increase in Healthcare Spending........22
1$100
   Opportunities Abound in the Developing Countries........23
Innovative Products Lend Traction to Growth........23
Reimbursements: “Under the Umbrella”........23
1$100
   Pricing Statistics On Select Ophthalmic Drugs in the US (2006) – A Perspective
  Builder........24
1$100
   Price Changes for Select Ophthalmic Drugs in the Year 2005........25
1$100
  4. AN OVERVIEW OF OPHTHALMIC DRUGS........2631 $2450  
   Anti Viral Drugs........26
Adenoviral Infections........26
Herpes Simplex Virus........26
Herpes Zoster (Varicella Zoster Disease)........26
1$100
   Corticosteroids........27
Loteprednol........27
Prednisolone........27
1$100
   Dexamethasone........28
Fluorometholones........28
Fluorometholone Alcohol........28
1$100
   Fluorometholone Acetate........29
Rimexolone........29
Clinical Efficacy of Steroids........29
1$100
   Topical Corticosteroid Drugs........30
Tapering of Steroid Intake........30
1$100
   Non-Steroids Anti Inflammatory Drugs (NSAID)........31
Use of Topical NSAIDs........31
Topical & Systemic NSAIDs........31
1$100
   Ketorolac: A Potent NSAID........32
Non-Steroidal Anti-Inflammatory Drugs........32
Antibiotics........32
Sodium Sulfacetamide........32
1$100
   Sulfisoxazole........33
Bacitracin........33
1$100
   Bacitracin and Polymyxin B: A Powerful Duo........34
Bacitracin, Polymyxin B and Neomycin: Three To Tango........34
Trimethoprim with Polymyxin B........34
1$100
   Chloramphenicol........35
Erythromycin........35
Gentamicin and Tobramycin........35
1$100
   Fluoroquinolones........36
Types of Fluoroquinolones........36
Ciprofloxacin........36
Gatifloxacin........36
Levofloxacin........36
1$100
   Moxifloxacin........37
Ofloxacin........37
Topical Antibiotic Drugs........37
1$100
   Ophthalmic Antihistamines........38
Azelastine........38
Emedastine........38
Epinastine........38
Ketotifen........38
1$100
   Olopatadine........39
Ophthalmic Mast-Cell Stabilizers........39
Cromolyn........39
Nedocromil Sodium........39
Pemirolast........39
1$100
   Drugs to Treat Glaucoma........40
Beta-Adrenergic Blockers or "Beta Blockers"........40
Timolol........40
Levobunolol........40
1$100
   Carteolol........41
Metipranolol........41
Betaxolol........41
Alpha-Adrenergic Agonists........41
1$100
   Carbonic Anhydrase Inhibitors........42
Acetazolamide........42
Dorzolamide........42
1$100
   Acetazolamide & Dorzolamide: How Good Is the Combo?........43
Miotics........43
Prostaglandins........43
Mydriatics & Cycloplegics........43
1$100
   Side Effects........44
Over-The-Counter (OTC) Ophthalmic Preparations........44
Artificial Tears........44
1$100
   Lubricating Ointments........45
Mast Cell Stabilizers........45
Antihistamines........45
1$100
   Phenylephrine........46
Naphazoline........46
Xylometazoline........46
Astringents........46
1$100
   Over-The-Counter Ophthalmic Preparations........471$100
   A Directory Listing of Major Ophthalmic Pharmaceutical Drugs ........48
Formulary Anti- Glaucoma Drugs........48
1$100
   Non-Formulary Anti- Glaucoma Drugs........49
Formulary Topical Anti-Glaucoma Drugs........49
1$100
   Formulary Ophthalmic Antiinfective/Corticosteroids Drugs........50
Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs........50
1$100
   Formulary Ophthalmic Corticosteroid Drugs........51
Non-Formulary Ophthalmic Corticosteroid Drugs........51
1$100
   Formulary Ophthalmic Topical Antibacterial Drugs........521$100
   Non-Formulary Ophthalmic Topical Antibacterial Drugs........53
Formulary Ophthalmic Topical Antiviral Drugs........53
Other Ophthalmic Formulary Drugs........53
1$100
   Other Ophthalmic Non-Formulary Drugs........542$200
   Pipeline Drugs........56
1$100
  5. OPHTHALMIC DISORDERS: A FREEZE FRAME........5728 $3450  
   The Human Eye: A Remarkable & Intriguing Organ of Sight........57
The Outer Layer........57
The Middle Layer........57
1$100
   The Inner Layer........58
Common Ophthalmic Disorders: An Exposition........58
Cataract........58
Causes........58
1$100
   Types of Cataract........59
Treatment Strategies........59
1$100
   How Widespread is the Disease?........60
Glaucoma........60
1$100
   Who’s At Risk?........61
Types of Glaucoma........61
Primary Open Angle Glaucoma (POAG)........61
Acute Angle-Closure Glaucoma (AACG)........61
1$100
   Congenital Glaucoma........62
Secondary Glaucoma........62
Treatment Strategies........62
1$100
   Anti- Glaucoma Ophthalmic Drugs........63
Table 1: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista Pharmaceuticals and Others (includes corresponding Graph/Chart)........63
1$350
   Table 2: Leading Glaucoma Pharmaceutical Products in the Global Market (Excluding US) (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/ Xalcom, Cosopt/Trusopt, Travatan/ Extravan, Lumigan/Ganfort, Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others (includes corresponding Graph/Chart)........64
How Widespread is the Disease?........64
1$350
   Table 3: Prevalence of Glaucoma in the World: Year 1999 and 2006 A Comparison (In 000 Individuals) (includes corresponding Graph/Chart)........651$350
   Is Marijuana A Potential Cure?........66
Age-Related Macular Degeneration (AMD)........66
Types of AMD........66
Dry AMD (Non-Neovascular)........66
1$100
   Wet AMD (Neovascular)........67
Causes........67
Treatment Strategies........67
1$100
   Nutrition & AMD........68
Diabetic Retinopathy........68
How Widespread is the Disease?........68
1$100
   Table 4: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)........69

Table 5: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)........69
1$350
   Table 6: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)........70
Treatment Strategies........70
1$350
   Market Awaits First Approved Drug; Off-label Use Continues........71
Diabetic Retinopathy Drug Market to Post Dramatic Growth........71
1$100
   Select Pipeline Drugs in Diabetic Retinopathy Market........72
Additional Trials Delay Arxxant’s Launch........72
1$100
   Lucentis Shows Promise in Diabetic Retinopathy Treatment........731$100
   Pycnogenol Continues to Appeal to Researchers........74
Robo4 Protein – A Potential Therapeutic for Diabetic Retinopathy........74
1$100
   Bevacizumab Bodes Potential As An Adjunct to Surgery PDR Treatment........75
Ocular Allergies........75
1$100
   Treatment Strategies........76
Immunotherapy: A Popular Anti-Allergy Treatment Approach........76
Ocular Inflammation: A Symptom of Ocular Allergies........76
1$100
   How Can Allergies Be Prevented?........771$100
   Conjunctivitis (Pink Eye)........78
Types of Conjunctivitis........78
1$100
   Pathogenesis........79
Treatment Strategies........79
1$100
   Keratitis........80
Types of Keratitis........80
Treatment Strategies........80
1$100
   Dry Eye........81
Why Are Tears So Crucial for Normal Eye Health?........81
1$100
   What Causes Dry Eye?........82
Treatment Strategies........82
Refractive Errors........82
1$100
   Causes for Refractive error........83
Treatment for Refractive Errors........83
Cost of Treatment........83
1$100
   Factors contributing to the Difference in Surgery Costs........84
1$100
  6. FDA APPROVALS AND PRODUCT LAUNCHES........855 $395  
   Zymaxid Obtains US FDA Approval........85
Carco Introduces Azelastine Ophthalmic Solution, 0.05%........85
Fera Pharmaceuticals Launches Neptazane Tablets........85
Banyu Pharmaceutical Introduces Cosopt Combinational Ophthalmic Solution........85
Bausch & Lomb Launches Soothe Xtra Hydration Eye Drops in the US........85
1$100
   Akorn Secures FDA Clearance for Erythromycin Ophthalmic Ointment........86
Teva Launches New Dorzolamide Hydrochloride Ophthalmic Solution........86
Caraco Pharmaceutical Laboratories Introduces New Ophthalmic Drug........86
Auxano Diagnostics Introduces Novel Point-of-Care Indicator System........86
Senju Pharmaceutical to Launch LUMIGAN® Ophthalmic Solution in Japan........86
1$100
   Sirion Receives FDA Approval for Zirgan........87
ISTA Pharmaceuticals Obtains FDA Approval for BepreveTM........87
Aton Pharma Reintroduces TIMOPTIC® in OCUDOSE®........87
1$100
   Novagali Pharma Obtains FDA Clearance for Phase III Study for Catioprost........88
Allergen Obtains FDA Approval for New Ophthalmic Product........88
Akorn Receives FDA Approval for Ciprofloxacin HCl Ophthalmic Solution USP........88
Akorn Introduces Akten Gel........88
Sirion Launches Topical Ophthalmic Drug........88
1$100
   FDC Obtains FDA Approval for Ciprofloxacin Ophthalmic Solution........89
Novagali Pharma to Introduce Cationorm® in France........89
Allergan Obtains FDA Clearance for Combigan........89
1$100
  7. FDA APPROVALS AND PRODUCT APPROVALS LAUNCHES IN THE RECENT PAST – A PERSPECTIVE
  BUILDER........90
10 $950  
   Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial........90
Alimera Conducts Phase III Medidur Trial........90
ISTA Pharmaceuticals Files NDA for Xibrom™ QD........90
AzaSite Receives FDA Approval........90
1$100
   Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections........91
Alimera Sciences Receives FDA Approval........91
Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan........91
Alcon Receives Marketing Approval for Patanol® in Japan........91
1$100
   Allergan Receives FDA Approval for Lumigan®........92
Allergan’s Ganfort® Receives Pan European License........92
Pfizer Receives Approval from EC to Market Macugen®........92
Akorn Gets Nod for Conducting Clinical Trial of AK-1015........92
Genentech ‘s Lucentis Receives FDA Approval........92
1$100
   MacuSight Receives FDA Approval for IND Application of Sirolimus........93
Sami Labs Receives Approval for Ocufors........93
Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic
  Solutions........93
Reckitt Benckiser Launches Two Eye Care Products........93
Alcon Launches DUOTRAV for Glaucoma Treatment........93
Macugen® Receives European Regulatory Approval........93
1$100
   Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug........94
Indoco Remedies to Launch Ophthalmic Drugs in America........94
Alcon's NEVANAC Receives FDA Approval........94
Fougera Obtains Approval for MetroGel®........94
1$100
   Allergan’s Alphagan P Receives FDA Approval........95
Santen Obtains Approval for Manufacturing and Marketing PAPILOCK........95
Akorn Launches Ophthalmic Drug Products........95
AlphaRx Formulates the Ophthalmic Product, Binoxan™........95
Alimera Sciences Introduces Online Consumer Ordering Facility........95
Fougera Adds Two Novel Products to its Ophthalmic Product Line........95
1$100
   Micro Vision Launches Anti-Glaucoma Drugs........96
Alcon Receives FDA Approval for Adding Susceptible Pathogens to VIGAMOX........96
BOL Receives FDA Approval for Ofloxacin........96
Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin Ophthalmic Solution........96
Vision Blue and DORC International Receives FDA Approval for Trypan Blue........96
Pfizer Receives FDA Nod for Macugen®........96
1$100
   Bausch & Lomb Bags FDA Approval for its Zylet™........97
ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment in the US........97
Falcon Unveils Trifluridine Ophthalmic Solution, 1%........97
Alimera Sciences Unveils Soothe™ Emollient Eye Drops........97
Novartis Introduces Zaditen in Japan........97
Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%........97
1$100
   Alcon Receives Approval for Olopatadine (Patanol)........98
Pharmacia Receives FDA Approval for Latanoprost Ophthalmic Solution........98
US FDA Approves Allergan’s New Acular LS 0.4% for Ocular Pain Reduction........98
Allergan Obtains FDA Approval for Zymar........98
Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop........98
Alcon Introduces Systane Lubricant Eye Drops........98
1$100
   Allergan Releases Restasis for Dry Eye Treatment........99
Biosyntrx Launches BioTears........99
Novartis to Introduce Pirenzepine Ophthalmic Gel........99
1$100
  8. RECENT INDUSTRY ACTIVITY........10012 $950  
   Bausch & Lomb Takes Over Zirgan®........100
Inspire and Santen Secure Japanese Approval for DIQUAS........100
Asahi Kasei Pharma and Altheos Enter into License Agreement........100
1$100
   OPKO Health Takes Over Pharmacos Exakta........101
Alcon Acquires Rights of Two Ophthalmic Pharmaceutical Products of Sirion........101
QLT Secures Rights from Othera Pharmaceuticals........101
Novartis Acquires 77% Stake in Alcon........101
1$100
   Pfizer Acquires Wyeth........102
Pieris Collaborates With Allergan to Treat Ocular Disorders........102
Bausch & Lomb Takes Over Commercial Assets of Tubilux........102
I-Therapeutix Changes Its Name to Ocular Therapeutix........102
Alcon Signs Collaborative Research Agreement with AstraZeneca........102
1$100
   Fera Pharmaceuticals Takes Over Seven Ophthalmic Ointments of Fougera........103
Bausch & Lomb Obtains Approval for Novel Ophthalmic Product........103
Alcon to Set Up Manufacturing Facility in Singapore........103
Inspire Pharmaceuticals Selects Clinipace to Conduct Phase II Clinical Trials........103
1$100
   Regeneron and Bayer to Extend Global Development Collaboration........104
Sucampo Obtains Rights to Commercialize Rescula........104
Santen and Merck Inks Licensing Agreement........104
1$100
   InSite Vision Inks Licensing and Distribution Agreement with Nitten........105
OPKO Terminates Phase III Trial of Bevasiranib........105
Sirion Therapeutics Signs Agreement with Advanced Vision Research........105
1$100
   Bausch & Lomb and Pfizer Ink Co-Promotion Agreement........106
NanoViricides Inks Material Transfer Agreement for Ophthalmic Antiviral........106
MacuCLEAR Partners with Mystic for Clinical Trials........106
1$100
   Sohm Inks Private Label and Development Agreement with Indian Company........107
Adeona Forms Research Collaboration with NNRI........107
Santen Receives Approval for TAPROS from MHLW........107
Otsuka and Acucela Ink Definitive Co-Development Deal for Rebamipide........107
1$100
   Canadian Bio Med Systems Obtains Licensing Rights for Two Ophthalmic Products........108
Novartis Acquires Minority Stake in Alcon from Nestle........108
OPKO Acquires Development and Commercialization Rights to Doxovir™........108
InSite Vision Inks Licensing and Distribution Agreement with Essex........108
1$100
   arGentis Pharmaceuticals Obtains License for New Ophthalmic Drug........109
Opko Health Finalizes Vidus Ocular Take Over........109
InSite Vision Inks Licensing and Distribution Agreement with Biem........109
Bausch & Lomb Inks Collaborative Research Agreement with Galapagos........109
1$100
   PRP and Jerini Ink License and Development Agreement with Jerini Ophthalmic........110
Akorn Inks Manufacturing and Supply Agreement with a US Company........110
Sirion and Bridge Pharma Sign Licensing Agreement........110
NicOx Extends Collaboration Agreement with Pfizer........110
Bausch & Lomb Acquires IOL Maker, Eyeonics........110
1$100
   Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution........111
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb........111
1$100
  9. CORPORATE ACTIVITY IN RECENT PAST – A PERSPECTIVE BUILDER........11211 $950  
   Genaera Corporation Quits Evizon Clinical Trials........112
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer
  Program........112
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs........112
Bausch & Lomb Acquire Soothe Products from Alimera........112
1$100
   Froptix, Acuity, eXegenics Merge to Form Opko Corporation........113
Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel
  Antioxidants........113
Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®........113
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections........113
QLT Takes Over Forsight Newco II, Inc........113
1$100
   Phase IV Clinical Trials Of Macugen®........114
Results Of Phase II Clinical Trials – Macugen®........114
Bausch & Lomb Purchases OTC Allergy Drugs of Alimera........114
1$100
   Phase II Trial of Acuity Pharmaceutical’s Bevasiranib........115
Advanced Refractive Technologies Acquires a Subsidiary of UTEK Corporation........115
Sirion Therapeutics Acquires Sytera........115
Teva Pharmaceuticals Acquires Ivax........115
Alcon Enters into an Agreement with Amgen........115
QLT Signs an Agreement with Retinagenix........115
1$100
   NicOx Enters into Licensing Agreement with Pfizer........116
OccuLogix Signs Agreement to Acquire SOLX........116
ISTA Receives License from Senju for Allergy Treatments........116
Acuity Receives License for Nchlorotaurine........116
Akorn and AVR Enter into Commercial Manufacturing & Supply Agreement........116
1$100
   Lantibio Signs Agreement with TRB Chemedica........117
Argentis and Southern College of Optometry Enter into Agreement........117
Bausch & Lomb Enters into Marketing Agreement with Novartis........117
Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly........117
Santen Pharmaceutical and CytoPathfinder Signs an Agreement........117
Kalypsys Inks an Agreement with Alcon, Inc........117
Combination RX Enters into a Collaboration Agreement with Fovea........117
1$100
   Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals........118
Isotechnika Sells Eye Drug Rights to Lux Biosciences........118
Alimera Sciences Collaborates With CYNACON........118
Novartis Inks an In-Licensing Agreement with Otsuka........118
1$100
   Alimera Sciences Commences Phase III Trials for Medidur™........119
SurModics Acquires InnoRx........119
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group........119
OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals........119
Pfizer Acquires Angiosyn........119
1$100
   Bausch & Lomb Collaborates with PTC Therapeutics........120
AMRI Enters into Research Collaboration with Alcon........120
Bausch & Lomb Bags License from Cephalon........120
PediaMed and Allergan Sign a Co-Promotion Agreement........120
SurModics Bags Option to Acquire Exclusive Rights from Rutgers University........120
Sankyo Co. and Santen Pharmaceutical Sign Agreement........120
Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation........120
1$100
   Apotex Inks Marketing Agreement with Akorn........121
Novartis Enters into an Agreement with Senju Pharmaceutical........121
Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical........121
Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution........121
AMO Takes Over VISX........121
Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer........121
1$100
   Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno........122
Alimera Sciences Inks Co-promotion Agreement with VISTAKON Pharmaceuticals........122
Akorn Inks a Purchase and Supply Agreement with FDC........122
ISTA Pharmaceuticals Receives Marketing License From Senju Pharmaceuticals........122
Pfizer Inc Acquires Pharmacia Corp........122
Allergan Takes Over Oculex Pharmaceuticals........122
Allergan Enters into an Agreement with Acadia........122
1$100
  10. FOCUS ON SELECT GLOBAL PLAYERS........1237 $595  
   Akorn, Inc. (USA)........123
Alcon, Inc. (Switzerland)........123
1$100
   Allergan, Inc. (USA)........1241$100
   Alimera Sciences, Inc. (USA)........125
Bausch & Lomb, Inc. (USA)........125
1$100
   Genvec, Inc. (USA)........126
Glaxosmithkline Plc. (UK)........126
Inspire Pharmaceuticals, Inc. (USA)........126
ISTA Pharmaceuticals, Inc. (USA)........126
1$100
   Merck & Co., Inc. (USA)........127
Novartis Ophthalmics (Canada)........127
1$100
   Opko Health, Inc. (USA)........128
Otsuka Pharmaceutical Co., Ltd. (Japan)........128
Pfizer, Inc. (USA)........128
QLT, Inc. (Canada)........128
1$100
   Santen Pharmaceutical Co. (Japan)........129
Santen Inc. (US)........129
1$100
  11. GLOBAL MARKET PERSPECTIVE........130   
   Table 7: World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1301$350
   Table 8: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1311$350
   Table 9: World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1321$350
   Table 10: World Recent Past, Current and Future Analysis for Glaucoma Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1331$350
   Table 11: World Historic Review for Glaucoma Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1341$350
   Table 12: World 11-Year Perspective for Glaucoma Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1351$350
   Table 13: World Recent Past, Current and Future Analysis for Ophthalmic Anti-allergy Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1361$350
   Table 14: World Historic Review for Ophthalmic Anti-allergy Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1371$350
   Table 15: World 11-Year Perspective for Ophthalmic Anti-allergy Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1381$350
   Table 16: World Recent Past, Current and Future Analysis for Ophthalmic Anti-infective Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1391$350
   Table 17: World Historic Review for Ophthalmic Anti-infective Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1401$350
   Table 18: World 11-Year Perspective for Ophthalmic Anti-infective Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1411$350
   Table 19: World Recent Past, Current and Future Analysis for Dry Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1421$350
   Table 20: World Historic Review for Dry Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1431$350
   Table 21: World 11-Year Perspective for Dry Eye Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1441$350
   Table 22: World Recent Past, Current and Future Analysis for Ophthalmic Anti-inflammatory Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1451$350
   Table 23: World Historic Review for Ophthalmic Anti-inflammatory Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2007 (includes corresponding Graph/Chart)........1461$350
   Table 24: World 11-Year Perspective for Ophthalmic Anti-inflammatory Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1471$350
   Table 25: World Recent Past, Current and Future Analysis for Back of Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1481$350
   Table 26: World Historic Review for Back of Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1491$350
   Table 27: World 11-Year Perspective for Back of Eye Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1501$350
   Table 28: World Recent Past, Current and Future Analysis for Other Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1511$350
   Table 29: World Historic Review for Other Ophthalmic Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1521$350
   Table 30: World 11-Year Perspective for Other Ophthalmic Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........153
1$350
  12. THE UNITED STATES........15422 $3950  
   A. Market Analysis........154
Outlook........154
Recession Relights Sales of OTC Drugs in Pharmaceutical Industry........154
Emphasis on Greater Awareness About Ophthalmic Disorders........154
1$100
   Growth Drivers In a Capsule........155
Impediments to Growth........155
Market Fact Sheet........155
1$100
   Glaucoma Market: A Primer........156
Patent Expiries of Key Glaucoma Drugs........156
Awareness Among Patients........156
1$100
   High Costs........157
Treatment Patterns Adopted By Doctors........157
The All Consuming Issue of Compliance........157
1$100
   Drug Brands & Their Patient Compliance Score........158
Market Share Statistics........158
Table 31: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (includes corresponding Graph/Chart)........158
1$350
   Table 32: The US Market for Glaucoma Pharmaceutical Products by Leading Drugs (2008 & 2009): Market Share Breakdown in terms of Prescription Volume for Xalatan, Lumigan, Alphagan P, Travatan and Others (includes corresponding Graph/Chart)........159

Table 33: Leading Glaucoma Pharmaceutical Products in the US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (includes corresponding Graph/Chart)........159
1$350
   Select Glaucoma Pharmaceuticals Presently Approved/ In Pipeline........160 1$100
   Table 34: Top 10 Brands of Eye/Lens Care in the US: Breakdown of Dollar and Unit Sales Through Drug Stores, Supermarkets and Discount Stores For the Year Ended November 2007 (In US$ 000 and Thousand Units)........161

Table 35: Top 5 Eye Care Products in the US: Breakdown of Dollar Sales Through Food, Drug and Mass Market Channels for the Year Ended July 2007 (In US$ Million) (includes corresponding Graph/Chart)........161
1$350
   Table 36: Age-Related Wet Macular Degeneration Market in the United States (2004-2006): Percentage Market Share Breakdown of Leading Players - QLT Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / Pfizer. (includes corresponding Graph/Chart)........162

Table 37: Ocular Allergy Market in the United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (includes corresponding Graph/Chart)........162
1$350
   Table 38: Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in the United States (2007): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and ISTA Pharmaceuticals (includes corresponding Graph/Chart)........163

Table 39: Age-Related Macular Degeneration Market in the United States (2006, 2009 & 2012): Dollar Sales of Major Branded Drugs – Visudyne, Macugen, and Lucentis (In US$ Million) (includes corresponding Graph/Chart)........163
1$350
   Major Anti-Glaucoma Drugs Available in the United States: Year 2006........164
Major Drugs Available in the United States for the Treatment of AMD: Year
  2005........164
1$100
   Drugs in the Pipeline for the Treatment of AMD in the United States: Year
  2005........165
Major Drugs Available in the United States for the Control of Dry Eye: Year
  2005........165
US Market for Dry Eye: Drugs in the Pipeline Year 2005........165
1$100
   Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005........166
Major Drugs Available in the United States for the Treatment of Ocular Allergies:
  Year 2005........166
1$100
   US Market for Ocular Allergies: Drugs in the Pipeline: Year 2005........167
Statistical Findings On Ophthalmic Diseases in the United States........167
Table 40: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet AMD & Intermediate Dry AMD by Age Group for the Year 2005 (includes corresponding Graph/Chart)........167
1$350
   Table 41: Prevalence of Age-Related Wet Macular Degeneration in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)........168

Table 42: Number of Individuals Treated for Wet AMD in the United States (In Thousands) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)........168

Table 43: Prevalence of Ocular Hypertension (OHT) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)........168
1$350
   Table 44: Prevalence of Primary Open Angle Glaucoma (POAG) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)........169

Table 45: Prevalence of Normal Tension Glaucoma (NTG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)........169

Table 46: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)........169
1$350
   Table 47: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)........170

Table 48: Number of Individuals Treated for Glaucoma in the United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (OHT), Primary Open Angle Glaucoma (POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma (PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) (includes corresponding Graph/Chart)........170
1$350
   Table 49: Prevalence of Ocular Allergy in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)........171

Table 50: Number of Individuals Treated for Ocular Allergy in the United States (In Million) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)........171

Table 51: Prevalence of Cataract in the United States: Percentage Breakdown by Age Group for the Year 2005 (includes corresponding Graph/Chart)........171
1$350
   Table 52: Prevalence of Cataract in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)........172

Table 53: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory Drugs) in the United States for the Years 2006, 2009 & 2012 ((In Millions) (includes corresponding Graph/Chart)........172

Table 54: Prevalence of Dry Eye in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)........172
1$350
   Table 55: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)........173
B. Market Analytics........173
Table 56: US Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........173
1$350
   Table 57: US Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1741$350
   Table 58: US 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........175
1$350
  13. CANADA........1764 $950  
   A. Market Analysis........176
Outlook........176
Lack of Awareness: A Key Issue........176
1$100
   B. Market Analytics........177
Table 59: Canadian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........177
1$350
   Table 60: Canadian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1781$350
   Table 61: Canadian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........179
1$350
  14. JAPAN........1804 $950  
   A. Market Analysis........180
Outlook........180
Growth Drivers........180
Market Data Statistics........180
Leading Ophthalmic Pharmaceutical Brands In the Market........180
1$100
   Table 62: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area – Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (includes corresponding Graph/Chart)........181
B. Market Analytics........181
Table 63: Japanese Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........181
1$350
   Table 64: Japanese Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1821$350
   Table 65: Japanese 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........183
1$350
  15. EUROPE........1848 $1950  
   A. Market Analysis........184
Outlook........184
A Market Primer........184
Drug Reimbursement in Europe........184
2$200
   B. Market Analytics........186
Table 66: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........186
1$350
   Table 67: European Historic Review for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1871$350
   Table 68: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........1881$350
   Table 69: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........1891$350
   Table 70: European Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1901$350
   Table 71: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........191
1$350
  15a. FRANCE........1924 $950  
   A. Market Analysis........192
Outlook........192
1$100
   B. Market Analytics........193
Table 72: French Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........193
1$350
   Table 73: French Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1941$350
   Table 74: French 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........195
1$350
  15b. GERMANY........1963 $950  
   Market Analysis........196
Table 75: German Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........196
1$350
   Table 76: German Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1971$350
   Table 77: German 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........198
1$350
  15c. ITALY........1993 $950  
   Market Analysis........199
Table 78: Italian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........199
1$350
   Table 79: Italian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2001$350
   Table 80: Italian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........201
1$350
  15d. THE UNITED KINGDOM........2024 $950  
   A. Market Analysis........202
Outlook........202
1$100
   B. Market Analytics........203
Table 81: UK Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........203
1$350
   Table 82: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2041$350
   Table 83: UK 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........205
1$350
  15e. SPAIN........2065 $950  
   A. Market Analysis........206
Outlook........206
How & Why the Health Insurance System in Spain is Conducive?........206
Pharmaceutical Reimbursement Reforms in Spain (1996-2002)........206
2$200
   B. Market Analytics........208
Table 84: Spanish Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........208
1$350
   Table 85: Spanish Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2091$350
   Table 86: Spanish 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........210
1$350
  15f. REST OF EUROPE........2114 $950  
   A. Market Analysis........211
Outlook........211
1$100
   B. Market Analytics........212
Table 87: Rest of Europe Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........212
1$350
   Table 88: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2131$350
   Table 89: Rest of Europe 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........214
1$350
  16. ASIA-PACIFIC........2154 $950  
   A. Market Analysis........215
Outlook........215
1$100
   B. Market Analytics........216
Table 90: Asia-Pacific Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........216
1$350
   Table 91: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2171$350
   Table 92: Asia-Pacific 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)........218
1$350
  17. LATIN AMERICA........2193 $950  
   Market Analysis........219
Table 93: Latin American Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........219
1$350
   Table 94: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2201$350
   Table 95: Latin American 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........221
1$350
  18. REST OF WORLD........2224 $950  
   A. Market Analysis........222
Outlook........222
1$100
   B. Market Analytics........223
Table 96: Rest of World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........223
1$350
   Table 97: Rest of World Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........2241$350
   Table 98: Rest of World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart)........2251$350
COMPETITION 327$995
  
Total Companies Profiled: 95 (including Divisions/Subsidiaries - 126)

Region/Country                 Players


The United States                 49   
Canada                             4
Japan                              8
Europe                            39
     France                        6
     Germany                       4
     The United Kingdom            4
     Italy                         4
     Spain                         2
     Rest of Europe               19
Asia-Pacific (Excluding Japan)    18
Latin America                      1
Middle-East                        7
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign